Our aim is to detect early and silent chronic kidney disease, to monitor metabolic disorders in patients with chronic kidney failure or cardiovascular disease, to improve their quality of life and to reduce morbidity and mortality..
FOUNDERS
Dr Gilles Schutz
Nephrologist and co-founder of Ki’tech
Dr. Gilles Schutz is a medical entrepreneur, founder of the Médifutur Group in 1992, which he chaired until 2018. He was president of the FHP-REIN union for 17 years.
Michel Fallah
Engineer and co-founder of Ki’tech
Michel Fallah is an electronics engineer, technologist and entrepreneur, with extensive experience in industrial projects and complex R&D projects.
EXPERTS OPINIONS
MICHAEL BASSLER
Ph.D, Head of Division « Diagnostics », Fraunhofer Institute for Microengineering and Microsystems IMM, Mayence, Allemagne
Patients are the main beneficiaries of the Ki’tech project, and there are many of them. We are on the verge of finding a seemingly simple, reproducible, and manufacturable solution that will help improve everyone’s health. Gilles Schutz and Michel Fallah are the right people to lead this project. They are experts.
SISI LI
Ph.D, Head of Group « Bioanalytics in Industrial Media », Fraunhofer Institute for Microengineering and Microsystems IMM, Mayence, Allemagne
We are convinced of the technological feasibility and the value of leveraging metabolic data. Ki’tech’s founders are open to the various solutions we propose. The collaboration evolves in a climate of mutual trust, an essential strength for long-term cooperation.
MEMBERS OF THE KI’TECH SCIENTIFIC COMMITTEE
Pr Denis FOUQUE
MD, PhD, ex-chef de service de néphrologie, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon
Pr Laetitia KOPPE
MD, chef du service de néphrologie, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon
Potassium regulation in patients with chronic kidney disease (CKD) is an ongoing concern. Currently, aside from blood tests, we have no means of continuously monitoring these patients. This tool could therefore represent a true technological innovation. Collaborating on its deployment represents a real opportunity to improve the care of our patients.